Relationship between resting 12-lead electrocardiogram and all-cause death in patients without structural heart disease: Shinken Database analysis.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
10 02 2021
Historique:
received: 12 08 2020
accepted: 11 01 2021
entrez: 11 2 2021
pubmed: 12 2 2021
medline: 5 10 2021
Statut: epublish

Résumé

Resting 12-lead electrocardiography is widely used for the detection of cardiac diseases. Electrocardiogram readings have been reported to be affected by aging and, therefore, can predict patient mortality. A total of 12,837 patients without structural heart disease who underwent electrocardiography at baseline were identified in the Shinken Database among those registered between 2010 and 2017 (n = 19,170). Using 438 electrocardiography parameters, predictive models for all-cause death and cardiovascular (CV) death were developed by a support vector machine (SVM) algorithm. During the observation period of 320.4 days, 55 all-cause deaths and 23 CV deaths were observed. In the SVM prediction model, the mean c-statistics of 10 cross-validation models with training and testing datasets were 0.881 ± 0.027 and 0.927 ± 0.101, respectively, for all-cause death and 0.862 ± 0.029 and 0.897 ± 0.069, respectively for CV death. For both all-cause and CV death, high values of permutation importance in the ECG parameters were concentrated in the QRS complex and ST-T segment. Parameters acquired from 12-lead resting electrocardiography could be applied to predict the all-cause and CV deaths of patients without structural heart disease. The ECG parameters that greatly contributed to the prediction were concentrated in the QRS complex and ST-T segment.

Sections du résumé

BACKGROUND
Resting 12-lead electrocardiography is widely used for the detection of cardiac diseases. Electrocardiogram readings have been reported to be affected by aging and, therefore, can predict patient mortality.
METHODS
A total of 12,837 patients without structural heart disease who underwent electrocardiography at baseline were identified in the Shinken Database among those registered between 2010 and 2017 (n = 19,170). Using 438 electrocardiography parameters, predictive models for all-cause death and cardiovascular (CV) death were developed by a support vector machine (SVM) algorithm.
RESULTS
During the observation period of 320.4 days, 55 all-cause deaths and 23 CV deaths were observed. In the SVM prediction model, the mean c-statistics of 10 cross-validation models with training and testing datasets were 0.881 ± 0.027 and 0.927 ± 0.101, respectively, for all-cause death and 0.862 ± 0.029 and 0.897 ± 0.069, respectively for CV death. For both all-cause and CV death, high values of permutation importance in the ECG parameters were concentrated in the QRS complex and ST-T segment.
CONCLUSIONS
Parameters acquired from 12-lead resting electrocardiography could be applied to predict the all-cause and CV deaths of patients without structural heart disease. The ECG parameters that greatly contributed to the prediction were concentrated in the QRS complex and ST-T segment.

Identifiants

pubmed: 33568066
doi: 10.1186/s12872-021-01864-3
pii: 10.1186/s12872-021-01864-3
pmc: PMC7874456
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

83

Références

J Electrocardiol. 2014 Nov-Dec;47(6):914-21
pubmed: 25194872
Age (Dordr). 2016 Apr;38(2):44
pubmed: 27039197
Int J Cardiol. 2020 Nov 11;:
pubmed: 33188796
Prim Care. 2018 Mar;45(1):25-44
pubmed: 29406943
Am J Cardiol. 2011 Dec 15;108(12):1735-40
pubmed: 21906704
Circ Arrhythm Electrophysiol. 2018 Dec;11(12):e006497
pubmed: 30541356
Europace. 2015 Jun;17(6):969-77
pubmed: 25355781
Eur Heart J. 2017 Oct 21;38(40):3017-3025
pubmed: 28662567
J Electrocardiol. 2018 Jul - Aug;51(4):652-657
pubmed: 29997006
J Natl Med Assoc. 2018 Apr;110(2):169-175
pubmed: 29580451
Int J Cardiol. 2017 Feb 1;228:219-224
pubmed: 27865189
Ann Noninvasive Electrocardiol. 2014 Nov;19(6):524-33
pubmed: 25367364
J Pers Med. 2014 Mar 07;4(1):65-78
pubmed: 25562143
Circ Res. 2017 Oct 13;121(9):1092-1101
pubmed: 28794054
J Electrocardiol. 2007 Jul;40(3):228-34
pubmed: 17276451
J Cardiovasc Electrophysiol. 2016 Jul;27(7):833-9
pubmed: 27094232
J Am Heart Assoc. 2014 Nov 21;3(6):e001387
pubmed: 25416036
Heart Rhythm. 2014 Oct;11(10):1701-6
pubmed: 24858812
Europace. 2018 Jun 1;20(FI1):f99-f107
pubmed: 29036623
Heart Rhythm. 2011 Jan;8(1):93-100
pubmed: 20868770
J Am Heart Assoc. 2017 Sep 20;6(9):
pubmed: 28931529
Circ J. 2016;80(3):639-49
pubmed: 26794283
PLoS One. 2019 Sep 9;14(9):e0221911
pubmed: 31499517

Auteurs

Naomi Hirota (N)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan. n-hirota@cvi.or.jp.

Shinya Suzuki (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Takuto Arita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Naoharu Yagi (N)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Takayuki Otsuka (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Mikio Kishi (M)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Hiroaki Semba (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Hiroto Kano (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Shunsuke Matsuno (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Yuko Kato (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Tokuhisa Uejima (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Yuji Oikawa (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Minoru Matsuhama (M)

Department of Cardiovascular Surgery, The Cardiovascular Institute, Tokyo, Japan.

Mitsuru Iida (M)

Department of Cardiovascular Surgery, The Cardiovascular Institute, Tokyo, Japan.

Tatsuya Inoue (T)

Department of Cardiovascular Surgery, The Cardiovascular Institute, Tokyo, Japan.

Junji Yajima (J)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Takeshi Yamashita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, 106-0031, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH